Advanced NanoTherapies raises more than $31m Series B for vascular-device development
S3 Ventures and an undisclosed strategic investor co-led the round as the company prepared US regulatory submissions and pivotal-study work.
Financing the path toward pivotal studies
Advanced NanoTherapies closed an oversubscribed Series B of more than $31 million, co-led by S3 Ventures and an undisclosed strategic investor. The T45 Fund and other new and existing backers participated.
The June 2 announcement linked the financing to manufacturing scale-up, US Investigational Device Exemption submissions for coronary indications and an early feasibility study below the knee. The company also planned to seek a pivotal-trial agreement with the FDA and identify sites outside the US for initial enrollment. These are development and regulatory steps for SirPlux Duo, which remains investigational rather than commercially approved.